VAXART BIOSCIENCES INC - CLINICAL TRIAL PLANNING ACTIVITIES FOR A PHASE 2B CLINICAL TRIAL THAT COMPARES VAXART'S XBB VACCINE CANDIDATE TO AN MRNA COMPARATOR TO EVALUATE EFFICACY FOR SYMPTOMATIC AND ASYMPTOMATIC DISEASE, SYSTEMIC AND MUCOSAL IMMUNE INDUCTION, AND ADVERSE
Key Details
Description
CLINICAL TRIAL PLANNING ACTIVITIES FOR A PHASE 2B CLINICAL TRIAL THAT COMPARES VAXART'S XBB VACCINE CANDIDATE TO AN MRNA COMPARATOR TO EVALUATE EFFICACY FOR SYMPTOMATIC AND ASYMPTOMATIC DISEASE, SYSTEMIC AND MUCOSAL IMMUNE INDUCTION, AND ADVERSE
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.